COVID prompts global surge in labs that handle dangerous pathogens

Smriti Mallapaty

Nature, 2022, vol. 610, issue 7932, 428-429

Abstract: India, Singapore and the Philippines are among those building new laboratories certified as biosafety level 3 or above, but some researchers worry about the costs and risks.

Keywords: Virology; Vaccines; Research management (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-03181-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:610:y:2022:i:7932:d:10.1038_d41586-022-03181-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-03181-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().